Health Condition 1: I00-I99- Diseases of the circulatory system
Conditions
Interventions
Intervention1: DAPAGLIFLOZIN: Dapagliflozin administered orally 10 mg once daily for a period of 6 months and LV diastolic parameters are measured at baseline and at the end of 6 months
Control Interv
Sponsors
DrSubbiah
Eligibility
Inclusion criteria
Inclusion criteria: All patients aged more than 18 years of age diagnosed with Diastolic Heart failure are included Diastolic Heart failure patients under treatment with either Dapagliflozin 10 mg or Telmisartan 40mg LVEF > 45% documented by echocardiography
Exclusion criteria
Exclusion criteria: Patients with systolic Heart failure with EF Uncontrolled Hypertension with systolic BP >140 mmhg or Diastolic Bp >90 mmhgare excluded Uncontrolled Diabetis mellitus with FBS >125 mg/dl or PPBS >200 mg/dl are excluded Patients who need step up treatment in Baseline Regimen dosage for Hypertension or Diabetes mellitus during course of study are excluded Patients who develop acute exacerbation or symptoms of congestive HF or those who need treatment with Diuretics during course of study are excluded Presence of cardiomyopathy due to infiltrative disorders- amyloidosis, sarcoidosis are excluded Dyspnea due to primary lung disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measuring improvemnt in LV diastolic function with 2D EchocardiographyTimepoint: Baseline, and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| First occurrence of decline in renal function from baselineTimepoint: Baseline, 24 weeks | — |
Countries
India
Contacts
Public ContactDrSubbiah
Saveetha Medical college and Hospital
Outcome results
None listed